Tumor drug shows promise for Tasmanian devils, pets and maybe humans

07/1/2013 | Sydney Morning Herald (Australia), The

A new plant-derived drug, EBC-46, was associated with regression or palliation in cancerous tumors in four Tasmanian devils, which have suffered massive losses to a contagious cancer. Veterinarian Jack Ayerbe, a director with the company that developed the drug, says he's used it successfully to treat some dogs and cats in his practice. Veterinarian Stephen Pyecroft, who helped develop and test the drug, says it may help treat captive devils and improve survival of their young, but it won't be a feasible treatment for wild animals. Human trials are planned as well.

View Full Article in:

Sydney Morning Herald (Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA